Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss unmet needs in advanced melanoma after checkpoint inhibition.
Back
Evolving Treatment Approaches After Checkpoint Inhibition in Advanced Melanoma
Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss novel treatment approaches in advanced melanoma after checkpoint inhibition.
Evolving Treatment Approaches After Checkpoint Inhibition in Advanced Melanoma
Episodes
All
All
Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss the role of interventional radiologists in melanoma management.
Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, dive into research behind oncolytic viruses in advanced melanoma.
Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, break down data from the IGNYTE trial of RP1 plus nivolumab in advanced melanoma after PD-1 inhibition.
Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss where RP1 plus nivolumab could fit in the advanced melanoma treatment paradigm.
Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss ongoing research to watch in advanced melanoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
3
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
4
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
5